Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.6500
-0.0500 (-7.14%)
At close: May 18, 2026
Lyra Therapeutics Employees
Lyra Therapeutics had 27 employees as of December 31, 2025. The number of employees decreased by 3 or -10.00% compared to the previous year.
Employees
27
Change (1Y)
-3
Growth (1Y)
-10.00%
Revenue / Employee
$14,741
Profits / Employee
-$1,071,074
Market Cap
1.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 27 | -3 | -10.00% |
| Dec 31, 2024 | 30 | -58 | -65.91% |
| Mar 31, 2024 | 109 | 45 | 70.31% |
| Dec 31, 2023 | 88 | 30 | 51.72% |
| Sep 30, 2023 | 78 | 19 | 32.20% |
| Jun 30, 2023 | 73 | 13 | 21.67% |
| Mar 31, 2023 | 64 | 7 | 12.28% |
| Dec 31, 2022 | 58 | 5 | 9.43% |
| Sep 30, 2022 | 59 | 5 | 9.26% |
| Jun 30, 2022 | 60 | 15 | 33.33% |
| Mar 31, 2022 | 57 | 14 | 32.56% |
| Dec 31, 2021 | 53 | 15 | 39.47% |
| Sep 30, 2021 | 54 | 21 | 63.64% |
| Jun 30, 2021 | 45 | 14 | 45.16% |
| Mar 31, 2021 | 43 | 9 | 26.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LakeShore Biopharma | 573 |
| International Stem Cell | 33 |
| CERo Therapeutics Holdings | 8 |
| ZyVersa Therapeutics | 6 |
| Abpro Holdings | 3 |
| Avenue Therapeutics | 1 |
Lyra Therapeutics News
- 4 weeks ago - Lyra Therapeutics announces intention to file Form 25 for delisting from Nasdaq - TheFly
- 4 weeks ago - Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC - GlobeNewsWire
- 3 months ago - Lyra Therapeutics common stock to be delisted by Nasdaq - TheFly
- 4 months ago - Why Is Lyra Therapeutics Stock (LYRA) Down Today? - TipRanks
- 4 months ago - Lyra Therapeutics suspends further development of LYR-210 - TheFly
- 4 months ago - Lyra Therapeutics Provides Corporate Update - GlobeNewsWire
- 6 months ago - Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07) - TheFly
- 6 months ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire